Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 9;9(3):e001764. doi: 10.1136/jitc-2020-001764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

RT+L19–IL2+anti-PD-L1 (trimodal) therapy effect is associated with high infiltration of NK and antigen-experienced CD8⁺ CD44⁺ T cells in the LLC model. (A) Treatment schedule for the evaluation of immunological parameters in the LLC model (n=5 mice per treatment arm), experiment was performed once. Stainings, flow cytometry data acquisition, and analysis of the samples were done in independent duplicates. (B) Representative flow cytometry dot plots of tumor-infiltrating CD8⁺ CD44⁺ (gated on CD3⁺ T cells) T cells 6 days after the start of treatment and quantification. (C) Representative flow cytometry dot plots of tumor-infiltrating T (CD3⁺ NK1.1^-), NKT (CD3⁺ NK1.1⁺) and NK (CD3^- NK1.1⁺) cells and quantifications of NKT and NK cell percentages. IgG, immunoglobulin G; LLC, Lewis lung carcinoma; PBS, phosphate-buffered saline; RT, radiotherapy.